Key facts
- This page summarizes Krishna Yeshwant's Form 4 filing for Verve Therapeutics, Inc. (VERV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Dec 2023, 16:30.
Krishna Yeshwant - 01 Dec 2023 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- VERV
- Reported as of
- 01 Dec 2023
- Net transaction value
- +$18,000,000
- SEC form
- 4
- Accepted by SEC
- 05 Dec 2023, 16:30:09 UTC
- Prior SEC filing
- 09 Nov 2023
- Next SEC filing
- 28 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Ashe, as Attorney-in-Fact for Krishna Yeshwant
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Krishna Yeshwant filed Form 4 for Verve Therapeutics, Inc. (VERV) on 05 Dec 2023.
Change
- Previous filing in this sequence was filed on 09 Nov 2023.
- Current net transaction value: +$18,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VERV
transaction
Common Stock
Purchase
- Transaction value
- $18,000,000
- Shares
- +1,800,000
- Change %
- Price
- $10.00
- Shares after
- 1,800,000
- Date
- 01 Dec 2023
- Ownership
- By GV 2023, L.P.
- Footnotes
- F1, F2
VERV
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,108,442
- Date
- 01 Dec 2023
- Ownership
- By GV 2017 L.P.
- Footnotes
- F3, F4
VERV
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,260,047
- Date
- 01 Dec 2023
- Ownership
- By GV 2019 L.P.
- Footnotes
- F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the "2023 Partnership"). GV 2023 GP, L.P. (the "2023 GP") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. ("GV 2023 LLC") is the general partner of the 2023 GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2023 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F2
(Continued from footnote 1) Dr. Yeshwant is an affiliate of the 2023 Partnership but does not have voting or dispositive power over the shares held by the 2023 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2023 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.
Footnote F3
The securities reported in this row are directly beneficially owned by GV 2017, L.P. (the "2017 Partnership"). GV 2017 GP, L.P. (the "2017 GP") is the general partner of the 2017 Partnership. GV 2017 GP, L.L.C. ("GV 2017 LLC") is the general partner of the 2017 GP. Alphabet Holdings is the sole member of GV 2017 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2017 Partnership. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F4
(Continued from footnote 3) Dr. Yeshwant is an affiliate of the 2017 Partnership but does not have voting or dispositive power over the shares held by the 2017 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2017 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.
Footnote F5
The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F6
(Continued from Footnote 5) Dr. Yeshwant is an affiliate of the 2019 Partnership but does not have voting or dispositive power over the shares held by the 2019 Partnership. Dr. Yeshwant disclaims beneficial ownership of the shares held by the 2019 Partnership except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.